{ "meta": { "publisher": "GLP-1 Tirzepatide Rx", "url": "https://glp1tirzepatiderx.com", "license": "Reuse permitted with attribution. Every price carries its verification date.", "last_verified": "2026-08-05", "disclosure_score_method": [ { "criterion": "Price published at all six dose tiers", "weight": 25 }, { "criterion": "Price does not rise as the dose escalates", "weight": 20 }, { "criterion": "Dispensing pharmacy or prescriber identified by name", "weight": 15 }, { "criterion": "No separate recurring membership fee", "weight": 10 }, { "criterion": "Prepaid term and its rate published", "weight": 10 }, { "criterion": "State availability published", "weight": 10 }, { "criterion": "Delivery formats published", "weight": 10 } ], "caveat": "Prices are recorded from provider-published material and, where marked, from third-party reviews. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before marketing." }, "trials": [ { "slug": "surmount-1", "name": "SURMOUNT-1", "year": 2022, "evidence_grade": 70, "grade_label": "Moderate", "grade_inputs": { "randomised": true, "blinded": true, "comparator": false, "size": true, "duration": true, "endpoint": false, "registered": true, "independent": false }, "blinding": "double", "comparator": "placebo", "participants": 2539, "endpoint_type": "surrogate", "sponsor": "Eli Lilly and Company", "industry_funded": true, "drug": "tirzepatide", "registration": "NCT04184622", "question": "Does tirzepatide cause weight loss in adults with obesity and without diabetes?", "citation": "N Engl J Med 2022;387:205-216", "url": "https://glp1tirzepatiderx.com/science/surmount-1/" }, { "slug": "surmount-5", "name": "SURMOUNT-5", "year": 2025, "evidence_grade": 55, "grade_label": "Moderate", "grade_inputs": { "randomised": true, "blinded": false, "comparator": true, "size": false, "duration": true, "endpoint": false, "registered": true, "independent": false }, "blinding": "open", "comparator": "active", "participants": 751, "endpoint_type": "surrogate", "sponsor": "Eli Lilly and Company", "industry_funded": true, "drug": "tirzepatide", "registration": "NCT05822830", "question": "Head-to-head: tirzepatide vs semaglutide for weight loss in adults with obesity and without diabetes.", "citation": "N Engl J Med 2025;392:1929-1942", "url": "https://glp1tirzepatiderx.com/science/surmount-5/" }, { "slug": "surmount-4", "name": "SURMOUNT-4", "year": 2024, "evidence_grade": 60, "grade_label": "Moderate", "grade_inputs": { "randomised": true, "blinded": true, "comparator": false, "size": false, "duration": true, "endpoint": false, "registered": true, "independent": false }, "blinding": "double", "comparator": "placebo", "participants": 670, "endpoint_type": "surrogate", "sponsor": "Eli Lilly and Company", "industry_funded": true, "drug": "tirzepatide", "registration": "NCT04660643", "question": "What happens if you stop tirzepatide after reaching a maintenance dose?", "citation": "JAMA 2024;331:38-48", "url": "https://glp1tirzepatiderx.com/science/surmount-4/" }, { "slug": "surmount-osa", "name": "SURMOUNT-OSA", "year": 2024, "evidence_grade": 60, "grade_label": "Moderate", "grade_inputs": { "randomised": true, "blinded": true, "comparator": false, "size": false, "duration": true, "endpoint": false, "registered": true, "independent": false }, "blinding": "double", "comparator": "placebo", "participants": 469, "endpoint_type": "surrogate", "sponsor": "Eli Lilly and Company", "industry_funded": true, "drug": "tirzepatide", "registration": "NCT05412004", "question": "Does tirzepatide treat obstructive sleep apnea in adults with obesity?", "citation": "N Engl J Med 2024;391:1193-1205", "url": "https://glp1tirzepatiderx.com/science/surmount-osa/" }, { "slug": "surpass-2", "name": "SURPASS-2", "year": 2021, "evidence_grade": 50, "grade_label": "Limited", "grade_inputs": { "randomised": true, "blinded": false, "comparator": true, "size": true, "duration": false, "endpoint": false, "registered": true, "independent": false }, "blinding": "open", "comparator": "active", "participants": 1879, "endpoint_type": "surrogate", "sponsor": "Eli Lilly and Company", "industry_funded": true, "drug": "tirzepatide", "registration": "NCT03987919", "question": "Tirzepatide vs semaglutide 1 mg in type 2 diabetes.", "citation": "N Engl J Med 2021;385:503-515", "url": "https://glp1tirzepatiderx.com/science/surpass-2/" }, { "slug": "surpass-cvot", "name": "SURPASS-CVOT", "year": 2025, "evidence_grade": 95, "grade_label": "High", "grade_inputs": { "randomised": true, "blinded": true, "comparator": true, "size": true, "duration": true, "endpoint": true, "registered": true, "independent": false }, "blinding": "double", "comparator": "active", "participants": 13299, "endpoint_type": "events", "sponsor": "Eli Lilly and Company", "industry_funded": true, "drug": "tirzepatide", "registration": "NCT04255433", "question": "Cardiovascular outcomes with tirzepatide vs dulaglutide in type 2 diabetes with established ASCVD.", "citation": "N Engl J Med 2025 (presented ADA 2025)", "url": "https://glp1tirzepatiderx.com/science/surpass-cvot/" }, { "slug": "summit", "name": "SUMMIT", "year": 2025, "evidence_grade": 75, "grade_label": "High", "grade_inputs": { "randomised": true, "blinded": true, "comparator": false, "size": false, "duration": true, "endpoint": true, "registered": true, "independent": false }, "blinding": "double", "comparator": "placebo", "participants": 731, "endpoint_type": "events", "sponsor": "Eli Lilly and Company", "industry_funded": true, "drug": "tirzepatide", "registration": "NCT04847557", "question": "Tirzepatide in heart failure with preserved ejection fraction and obesity.", "citation": "N Engl J Med 2025;392:427-437", "url": "https://glp1tirzepatiderx.com/science/summit/" }, { "slug": "surmount-3", "name": "SURMOUNT-3", "year": 2023, "evidence_grade": 60, "grade_label": "Moderate", "grade_inputs": { "randomised": true, "blinded": true, "comparator": false, "size": false, "duration": true, "endpoint": false, "registered": true, "independent": false }, "blinding": "double", "comparator": "placebo", "participants": 806, "endpoint_type": "surrogate", "sponsor": "Eli Lilly and Company", "industry_funded": true, "drug": "tirzepatide", "registration": "NCT04657016", "question": "Does tirzepatide add further loss after a successful intensive lifestyle program?", "citation": "Nat Med 2023;29:2909-2918", "url": "https://glp1tirzepatiderx.com/science/surmount-3/" }, { "slug": "surmount-2", "name": "SURMOUNT-2", "year": 2023, "evidence_grade": 60, "grade_label": "Moderate", "grade_inputs": { "randomised": true, "blinded": true, "comparator": false, "size": false, "duration": true, "endpoint": false, "registered": true, "independent": false }, "blinding": "double", "comparator": "placebo", "participants": 938, "endpoint_type": "surrogate", "sponsor": "Eli Lilly and Company", "industry_funded": true, "drug": "tirzepatide", "registration": "NCT04657003", "question": "Tirzepatide for obesity in adults who also have type 2 diabetes.", "citation": "Lancet 2023;402:613-626", "url": "https://glp1tirzepatiderx.com/science/surmount-2/" }, { "slug": "attain-1", "name": "ATTAIN-1", "year": 2026, "evidence_grade": 70, "grade_label": "Moderate", "grade_inputs": { "randomised": true, "blinded": true, "comparator": false, "size": true, "duration": true, "endpoint": false, "registered": true, "independent": false }, "blinding": "double", "comparator": "placebo", "participants": 3127, "endpoint_type": "surrogate", "sponsor": "Eli Lilly and Company", "industry_funded": true, "drug": "orforglipron", "registration": "NCT05869903", "question": "Oral small-molecule GLP-1 (orforglipron) for weight management.", "citation": "N Engl J Med 2025 / FDA approval April 2026", "url": "https://glp1tirzepatiderx.com/science/attain-1/" }, { "slug": "step-1", "name": "STEP-1", "year": 2021, "evidence_grade": 70, "grade_label": "Moderate", "grade_inputs": { "randomised": true, "blinded": true, "comparator": false, "size": true, "duration": true, "endpoint": false, "registered": true, "independent": false }, "blinding": "double", "comparator": "placebo", "participants": 1961, "endpoint_type": "surrogate", "sponsor": "Novo Nordisk", "industry_funded": true, "drug": "semaglutide", "registration": "NCT03548935", "question": "Semaglutide 2.4 mg for weight management without diabetes.", "citation": "N Engl J Med 2021;384:989-1002", "url": "https://glp1tirzepatiderx.com/science/step-1/" }, { "slug": "select", "name": "SELECT", "year": 2023, "evidence_grade": 85, "grade_label": "High", "grade_inputs": { "randomised": true, "blinded": true, "comparator": false, "size": true, "duration": true, "endpoint": true, "registered": true, "independent": false }, "blinding": "double", "comparator": "placebo", "participants": 17604, "endpoint_type": "events", "sponsor": "Novo Nordisk", "industry_funded": true, "drug": "semaglutide", "registration": "NCT03574597", "question": "Does semaglutide reduce cardiovascular events in people with obesity but without diabetes?", "citation": "N Engl J Med 2023;389:2221-2232", "url": "https://glp1tirzepatiderx.com/science/select/" }, { "slug": "step-8", "name": "STEP-8", "year": 2022, "evidence_grade": 55, "grade_label": "Moderate", "grade_inputs": { "randomised": true, "blinded": false, "comparator": true, "size": false, "duration": true, "endpoint": false, "registered": true, "independent": false }, "blinding": "open", "comparator": "active", "participants": 338, "endpoint_type": "surrogate", "sponsor": "Novo Nordisk", "industry_funded": true, "drug": "semaglutide", "registration": "NCT03611582", "question": "Semaglutide 2.4 mg vs liraglutide 3.0 mg.", "citation": "JAMA 2022;327:138-150", "url": "https://glp1tirzepatiderx.com/science/step-8/" }, { "slug": "gip-mechanism", "name": "GIP receptor pharmacology", "year": 2025, "evidence_grade": 5, "grade_label": "Low", "grade_inputs": { "randomised": false, "blinded": false, "comparator": false, "size": false, "duration": false, "endpoint": false, "registered": false, "independent": true }, "blinding": "none", "comparator": "none", "participants": null, "endpoint_type": "surrogate", "sponsor": "Various", "industry_funded": false, "drug": "tirzepatide", "registration": "\u2014", "question": "Why does adding GIP agonism to GLP-1 agonism produce more weight loss?", "citation": "Reviews in Cell Metab / Nat Rev Endocrinol 2023\u20132025", "url": "https://glp1tirzepatiderx.com/science/gip-mechanism/" }, { "slug": "surpass-1", "name": "SURPASS-1", "year": "2021", "evidence_grade": 45, "grade_label": "Limited", "grade_inputs": { "randomised": true, "blinded": true, "comparator": false, "size": false, "duration": false, "endpoint": false, "registered": true, "independent": false }, "blinding": "double", "comparator": "placebo", "participants": 478, "endpoint_type": "surrogate", "sponsor": "Eli Lilly and Company", "industry_funded": true, "drug": "tirzepatide", "registration": "NCT03954834", "question": "Does tirzepatide alone control blood glucose in type 2 diabetes not already on medication?", "citation": "Lancet 2021;398:143-155", "url": "https://glp1tirzepatiderx.com/science/surpass-1/" }, { "slug": "surpass-3", "name": "SURPASS-3", "year": "2021", "evidence_grade": 65, "grade_label": "Moderate", "grade_inputs": { "randomised": true, "blinded": false, "comparator": true, "size": true, "duration": true, "endpoint": false, "registered": true, "independent": false }, "blinding": "open", "comparator": "active", "participants": 1444, "endpoint_type": "surrogate", "sponsor": "Eli Lilly and Company", "industry_funded": true, "drug": "tirzepatide", "registration": "NCT03882970", "question": "How does tirzepatide compare with basal insulin added to metformin?", "citation": "Lancet 2021;398:583-598", "url": "https://glp1tirzepatiderx.com/science/surpass-3/" }, { "slug": "surpass-4", "name": "SURPASS-4", "year": "2021", "evidence_grade": 65, "grade_label": "Moderate", "grade_inputs": { "randomised": true, "blinded": false, "comparator": true, "size": true, "duration": true, "endpoint": false, "registered": true, "independent": false }, "blinding": "open", "comparator": "active", "participants": 2002, "endpoint_type": "surrogate", "sponsor": "Eli Lilly and Company", "industry_funded": true, "drug": "tirzepatide", "registration": "NCT03730662", "question": "Is tirzepatide safe and effective in people with type 2 diabetes at high cardiovascular risk?", "citation": "Lancet 2021;398:1811-1824", "url": "https://glp1tirzepatiderx.com/science/surpass-4/" }, { "slug": "surpass-j-mono", "name": "SURPASS J-mono", "year": "2022", "evidence_grade": 70, "grade_label": "Moderate", "grade_inputs": { "randomised": true, "blinded": true, "comparator": true, "size": false, "duration": true, "endpoint": false, "registered": true, "independent": false }, "blinding": "double", "comparator": "active", "participants": 636, "endpoint_type": "surrogate", "sponsor": "Eli Lilly and Company", "industry_funded": true, "drug": "tirzepatide", "registration": "NCT03861052", "question": "Does tirzepatide work the same way in a Japanese population?", "citation": "Lancet Diabetes Endocrinol 2022;10:623-633", "url": "https://glp1tirzepatiderx.com/science/surpass-j-mono/" }, { "slug": "tirzepatide-cv-meta", "name": "Tirzepatide cardiovascular meta-analysis", "year": "2022", "evidence_grade": 95, "grade_label": "High", "grade_inputs": { "randomised": true, "blinded": true, "comparator": true, "size": true, "duration": true, "endpoint": true, "registered": true, "independent": false }, "blinding": "double", "comparator": "active", "participants": 13000, "endpoint_type": "events", "sponsor": "Eli Lilly and Company", "industry_funded": true, "drug": "tirzepatide", "registration": "Not applicable \u2014 pre-specified meta-analysis of registered trials", "question": "Does tirzepatide increase cardiovascular risk across the trial programme?", "citation": "Nat Med 2022;28:591-598", "url": "https://glp1tirzepatiderx.com/science/tirzepatide-cv-meta/" }, { "slug": "time-to-plateau", "name": "Time to weight plateau (SURMOUNT-1 and -4 analysis)", "year": "2025", "evidence_grade": 70, "grade_label": "Moderate", "grade_inputs": { "randomised": true, "blinded": true, "comparator": false, "size": true, "duration": true, "endpoint": false, "registered": true, "independent": false }, "blinding": "double", "comparator": "placebo", "participants": 2539, "endpoint_type": "surrogate", "sponsor": "Eli Lilly and Company", "industry_funded": true, "drug": "tirzepatide", "registration": "NCT04184622 and NCT04660643", "question": "When does weight loss on tirzepatide actually stop?", "citation": "Clin Obes 2025", "url": "https://glp1tirzepatiderx.com/science/time-to-plateau/" } ] }